Celldex Therapeutics Operating Income 2010-2022 | CLDX
Celldex Therapeutics operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Celldex Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-71 |
| 2020 |
$-63 |
| 2019 |
$-55 |
| 2018 |
$-156 |
| 2017 |
$-122 |
| 2016 |
$-133 |
| 2015 |
$-130 |
| 2014 |
$-122 |
| 2013 |
$-81 |
| 2012 |
$-58 |
| 2011 |
$-43 |
| 2010 |
$-6 |
| 2009 |
$-37 |
Celldex Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-23 |
| 2021-12-31 |
$-20 |
| 2021-09-30 |
$-21 |
| 2021-06-30 |
$-13 |
| 2021-03-31 |
$-17 |
| 2020-12-31 |
$-25 |
| 2020-09-30 |
$-14 |
| 2020-06-30 |
$-11 |
| 2020-03-31 |
$-13 |
| 2019-12-31 |
$-13 |
| 2019-09-30 |
$-12 |
| 2019-06-30 |
$-12 |
| 2019-03-31 |
$-18 |
| 2018-12-31 |
$-12 |
| 2018-09-30 |
$-8 |
| 2018-06-30 |
$-17 |
| 2018-03-31 |
$-120 |
| 2017-12-31 |
$-26 |
| 2017-09-30 |
$-32 |
| 2017-06-30 |
$-29 |
| 2017-03-31 |
$-35 |
| 2016-12-31 |
$-35 |
| 2016-09-30 |
$-30 |
| 2016-06-30 |
$-32 |
| 2016-03-31 |
$-36 |
| 2015-12-31 |
$-33 |
| 2015-09-30 |
$-32 |
| 2015-06-30 |
$-33 |
| 2015-03-31 |
$-31 |
| 2014-12-31 |
$-32 |
| 2014-09-30 |
$-30 |
| 2014-06-30 |
$-29 |
| 2014-03-31 |
$-31 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$-23 |
| 2013-06-30 |
$-19 |
| 2013-03-31 |
$-17 |
| 2012-12-31 |
$-17 |
| 2012-09-30 |
$-15 |
| 2012-06-30 |
$-13 |
| 2012-03-31 |
$-13 |
| 2011-12-31 |
$-12 |
| 2011-09-30 |
$-11 |
| 2011-06-30 |
$-10 |
| 2011-03-31 |
$-10 |
| 2010-12-31 |
$21 |
| 2010-09-30 |
$-9 |
| 2010-06-30 |
$-9 |
| 2010-03-31 |
$-9 |
| 2009-12-31 |
$-13 |
| 2009-09-30 |
$-7 |
| 2009-06-30 |
$-9 |
| 2009-03-31 |
$-8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.262B |
$0.005B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
